These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38823178)
1. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting. Wu Q; Jin Y; Li S; Guo X; Sun W; Liu J; Li Q; Niu D; Zou Y; Du X; Li Y; Zhao T; Li Z; Li X; Ren G Int Immunopharmacol; 2024 Jul; 136():112305. PubMed ID: 38823178 [TBL] [Abstract][Full Text] [Related]
2. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma. Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179 [TBL] [Abstract][Full Text] [Related]
3. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746 [TBL] [Abstract][Full Text] [Related]
4. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550 [TBL] [Abstract][Full Text] [Related]
5. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930 [TBL] [Abstract][Full Text] [Related]
6. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743 [TBL] [Abstract][Full Text] [Related]
7. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro. Burke S; Shergold A; Elder MJ; Whitworth J; Cheng X; Jin H; Wilkinson RW; Harper J; Carroll DK Cancer Immunol Immunother; 2020 Jun; 69(6):1015-1027. PubMed ID: 32088771 [TBL] [Abstract][Full Text] [Related]
8. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Janke M; Peeters B; de Leeuw O; Moorman R; Arnold A; Fournier P; Schirrmacher V Gene Ther; 2007 Dec; 14(23):1639-49. PubMed ID: 17914407 [TBL] [Abstract][Full Text] [Related]
10. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice. Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432 [TBL] [Abstract][Full Text] [Related]
11. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy. Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956 [TBL] [Abstract][Full Text] [Related]
12. Combination Immunotherapy of Oncolytic Flu-Vectored Virus and Programmed Cell Death 1 Blockade Enhances Antitumor Activity in Hepatocellular Carcinoma. Yu H; Sun F; Xu Y; Yang H; Tian C; Li C; Kang Y; Hao L; Yang P Hum Gene Ther; 2024 Mar; 35(5-6):177-191. PubMed ID: 38386514 [TBL] [Abstract][Full Text] [Related]
13. [Progress in using Newcastle disease virus for tumor therapy: a review]. Wu Y; Hao J; Li D Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105 [TBL] [Abstract][Full Text] [Related]
14. Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model. Yurchenko KS; Glushchenko AV; Gulyaeva MA; Bi Y; Chen J; Shi W; Adamenko LS; Shestopalov AM Viruses; 2021 Mar; 13(4):. PubMed ID: 33806229 [TBL] [Abstract][Full Text] [Related]
15. Newcastle disease virus as an oncolytic agent. Ravindra PV; Tiwari AK; Sharma B; Chauhan RS Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097 [TBL] [Abstract][Full Text] [Related]
16. Oncolytic Activity of Sindbis Virus with the Help of GM-CSF in Hepatocellular Carcinoma. Shi X; Sun K; Li L; Xian J; Wang P; Jia F; Xu F Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000311 [TBL] [Abstract][Full Text] [Related]
17. Newcastle disease virus: a promising agent for tumour immunotherapy. Zhao L; Liu H Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810 [TBL] [Abstract][Full Text] [Related]
18. Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy. Wu Y; He J; Geng J; An Y; Ye X; Yan S; Yu Q; Yin J; Zhang Z; Li D Eur J Pharmacol; 2017 May; 802():85-92. PubMed ID: 28246027 [TBL] [Abstract][Full Text] [Related]
19. Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy. Ren G; Tian G; Liu Y; He J; Gao X; Yu Y; Liu X; Zhang X; Sun T; Liu S; Yin J; Li D Technol Cancer Res Treat; 2016 Oct; 15(5):NP83-94. PubMed ID: 26303327 [TBL] [Abstract][Full Text] [Related]
20. Apoptin enhances the oncolytic properties of Newcastle disease virus. Wu Y; Zhang X; Wang X; Wang L; Hu S; Liu X; Meng S Intervirology; 2012; 55(4):276-86. PubMed ID: 21865658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]